This is a rare commercial setback for ABT, who invested a lot in the development of ABSORB and the bioabsorbable-stent technology on which it is based. Although ABSORB is still on the market in the US, the sales are apt to be small following the data reported in #msg-129683267.
ABT is trading flat today.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.